Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H33N3O4.H3O4P |
Molecular Weight | 525.5317 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.CN(C)CCCNC(=O)C(\COC1=C2C=CC=CC2=CC=C1)=C\CCCCC(=O)NO
InChI
InChIKey=UOKSXAOZBSWROR-DOELHFPHSA-N
InChI=1S/C24H33N3O4.H3O4P/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22;1-5(2,3)4/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28);(H3,1,2,3,4)/b20-11+;
Molecular Formula | H3O4P |
Molecular Weight | 97.9952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H33N3O4 |
Molecular Weight | 427.5365 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
CG-200745 is a novel inhibitor of histone deacetylases (HDACs), initially developed by CrystalGenomics, Inc for treatment of various hematological and solid cancers. Combinations of CG-200745 with SN38 (the active form of irinotecan), or oxaliplatin were more effective than the agents alone when used to inhibit the growth of HCT116 cells. The protein expressions of acetyl-H3, p21, caspase-3, -8, and -9, PARP, and XIAP were affected in a time- and dose-dependent manner in HCT116 cells treated with the CG-200745 alone or combined CG-200745 and SN-38. In HCT116 xenografts, the HDACI CG-200745 in combination with irinotecan dramatically inhibited tumor growth without showing additive toxicity.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21773733
mice 30 mg/kg, 5 days/week
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:13:53 GMT 2023
by
admin
on
Sat Dec 16 16:13:53 GMT 2023
|
Record UNII |
QA3Y8EZG57
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
699019
Created by
admin on Sat Dec 16 16:13:53 GMT 2023 , Edited by admin on Sat Dec 16 16:13:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QA3Y8EZG57
Created by
admin on Sat Dec 16 16:13:53 GMT 2023 , Edited by admin on Sat Dec 16 16:13:53 GMT 2023
|
PRIMARY | |||
|
146048056
Created by
admin on Sat Dec 16 16:13:53 GMT 2023 , Edited by admin on Sat Dec 16 16:13:53 GMT 2023
|
PRIMARY | |||
|
2173017-02-0
Created by
admin on Sat Dec 16 16:13:53 GMT 2023 , Edited by admin on Sat Dec 16 16:13:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|